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Introduction
Bone mineral density (BMD) is considered an important
determinant for bone strength and fracture risk in human bone
disorders. Bones are renewed throughout life through bone
remodeling, i.e. synthesis of bone matrix by osteoblasts (of
mesenchymal origin) and bone resorption by osteoclasts (of
hematopoietic origin) (Jilka, 2003). In osteoporosis,
perturbations in local cytokines, growth factors, systemic
hormones and transcription factors cause imbalance between
bone formation and resorption, resulting in net bone loss
(Karsenty, 1999). Peak bone mass, the result of net bone
accrual in early life and with a maximum in the second and
third decade of life, is greatly influenced by genetic factors (50-
85%) (Giguere and Rousseau, 2000; Ralston, 2002; Nguyen et
al., 2003; Ralston and de Crombrugghe, 2006). BMD depends
on peak bone mass, but also on the rate of bone loss in later
life. Although polymorphisms of several genes associated with
reduced bone mass and increased fracture risk have been
identified, e.g. bone morphogenetic protein-2 (BMP-2), LRP5
and Collagen I (Grant et al., 1996; Johnson et al., 2004; Mundy,
2006; Ralston, 2002), the mechanisms controlling the variation
of bone loss rate are mostly unknown.
In skeletal tissue, mesenchymal bone cell development from
a common progenitor cell (Pittenger et al., 1999) is under
transcriptional regulation: Runx2 and osterix (Osx) (Ducy,
2000; Nakashima et al., 2002) are crucial for normal
osteogenesis, whereas Sox5, Sox6 and Sox9 (Lefebvre et al.,
1998) and PPAR ligands (Lecka-Czernik et al., 2002)
influence chondrocyte and adipocyte development, respectively.
Several transcription factors in the Sox family [related to sex-
determining region Y (SRY) proteins] are involved in skeletal
development in addition to their roles in developmental
processes in other tissues (Schilham et al., 1996; Hong and
Saint-Jeannet, 2005). Sox4 contains the Sox family
characteristic high mobility group (HMG) box, and is highly
conserved in human, mouse, chicken (Maschhoff et al., 2003)
and fish (Hett and Ludwig, 2005; Mavropoulos et al., 2005),
and expressed in brain, gonads, lung, heart and thymus
(Schilham et al., 1996). It is implicated in lymphocyte
differentiation (Schilham et al., 1997; van de Wetering et al.,
The transcription factor Sox4 is vital for fetal development,
as Sox4–/– homozygotes die in utero. Sox4 mRNA is
expressed in the early embryonic growth plate and is
regulated by parathyroid hormone, but its function in bone
modeling/remodeling is unknown. We report that Sox4+/–
mice exhibit significantly lower bone mass (by dual-energy
X-ray absorptiometry) from an early age, and fail to
obtain the peak bone mass of wild-type (WT) animals.
Microcomputed tomography (CT), histomorphometry
and biomechanical testing of Sox4+/– bones show reduced
trabecular and cortical thickness, growth plate width,
ultimate force and stiffness compared with WT. Bone
formation rate (BFR) in 3-month-old Sox4+/– mice is 64%
lower than in WT. Primary calvarial osteoblasts from
Sox4+/– mice demonstrate markedly inhibited proliferation,
differentiation and mineralization. In these cultures,
osterix (Osx) and osteocalcin (OCN) mRNA expression was
reduced, whereas Runx2 mRNA was unaffected. No
functional defects were found in osteoclasts. Silencing of
Sox4 by siRNA in WT osteoblasts replicated the defects
observed in Sox4+/– cells. We demonstrate inhibited
formation and altered microarchitecture of bone in Sox4+/–
mice versus WT, without apparent defects in bone
resorption. Our results implicate the transcription factor
Sox4 in regulation of bone formation, by acting upstream
of Osx and independent of Runx2.
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1993), cancer (Liu et al., 2006; Pramoonjago et al., 2006) and
apoptosis (Ahn et al., 2002; Hur et al., 2004; Pramoonjago et
al., 2006).
Our group first reported expression of Sox4 in skeletal
tissue; Sox4 mRNA is highly expressed in normal and clonal
osteoblasts of human and rat origin, where it is stimulated by
parathyroid hormone (PTH), and the transcript is
predominantly localized in hypertrophic chondrocytes in
developing mouse hindlimbs (Reppe et al., 2000). We recently
demonstrated elevated SOX4 mRNA levels in bone biopsies
from patients with active primary hyperparathyroidism
compared with levels after successful surgery and PTH
normalization (Reppe et al., 2006). Sekiya et al. demonstrated
that induction of chondrogenesis in human bone marrow
stromal cells led to a transient, eightfold stimulation of Sox4,
preceding the upregulation of Sox5, Sox6 and Sox9 mRNAs
(Sekiya et al., 2002). Sox5, Sox6 and Sox9 regulate
chondrocyte differentiation (Lefebvre et al., 1998), and Sox8
seems to regulate osteoblast differentiation through Runx2
inhibition (Schmidt et al., 2005).
In the present study we have examined the role of Sox4 in
postnatal bone development in mice, with the hypothesis that
the Sox4 gene affects normal bone formation. Preliminary
investigations indicated that healthy Sox4+/– mice developed
osteopenia (Nissen-Meyer et al., 2004; Nissen-Meyer et al.,
2005). Because ablation of both copies of the Sox4 gene in
mice leads to circulatory failure in utero (Schilham et al.,
1996), we designed a longitudinal study of Sox4+/– mice and
age- and gender-matched wild-type (WT) littermates,
examining functional parameters of bone metabolism,
histomorphometry, microcomputed tomography (CT) and
bone mineral densitometry related to age. To explore molecular
and cellular mechanisms responsible for the observed
osteopenia, we used primary cultures of differentiating Sox4+/–
and WT calvarial osteoblasts to assess proliferation,
differentiation and mineralization properties. In addition, we
studied whether silencing of Sox4 in WT osteoblasts using
small interfering RNA (siRNA) treatment could mimic the
haploinsufficient phenotype of Sox4+/–-derived osteoblasts.
Our data indicate an important role for Sox4 in the regulation
of bone formation and homeostasis.
Results
General morbidity of heterozygous Sox4+/– mice is low
Sox4+/– offspring was morphologically indistinguishable from
WT, with an overall normal life span. However, rectal
prolapses were more frequently observed in the Sox4+/– mice
than in the WT; they also had somewhat reduced fertility.
Internal organs and the skeleton were examined at time of
sacrifice by an experienced pathologist (FPR) and apart from
abdominal inclusion cysts in some females, no macroscopical
differences were found between Sox4+/– and WT controls.
Sox4+/– mice were only slightly smaller than their
littermates, as determined by total body mass (Table 1). Three-
month-old Sox4+/– mice had significantly shorter femurs than
WT (–4.6% for males, P<0.001; similar for females), whereas
the differences were non-significant for older mice (not
shown).
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Table 1. Body mass, body fat and bone mineral density of WT and Sox4+/– mice
Males Females
WT (n=19) Sox4+/– (n=11) WT (n=18) Sox4+/– (n=14)
Young mice (10 weeks)
Body mass (g) 24.2±2.2 24.2±2.0 19.8±0.8 18.2±1.7B
Body fat (%) 12.8±2.0 13.0±2.1 13.8±1.5 13.3±2.5
Bone area (cm2) 8.65±0.59 8.78±0.30 8.35±0.39 8.08±0.45
BMD (mg/cm2)
Total body 46.47±2.42 44.40±2.18C 43.89±1.19 40.57±2.13A
Lumbar spine 67.11±4.62 61.17±3.43B 62.81±4.52 57.69±5.29B
Trochanter 80.87±7.52 76.80±5.79 73.79±4.86 67.61±6.39B
Femoral shaft 61.01±7.69 60.15±5.08 50.55±4.13 48.81±2.84
TibiaD 87.81±5.85 80.80±4.47C 77.66±4.00 65.90±5.66B
WT (n=18) Sox4+/– (n=8) WT (n=20) Sox4+/– (n=10)
Adult mice (6 months)
Total mass (g) 31.2±2.7 29.5±2.5 24.6±2.7 23.6±2.4
Body fat (%) 17.0±5.7 19.1±3.4 19.1±4.6 22.3±3.4
Bone area (cm2) 9.97±0.48 9.51±0.40C 9.36±0.43 8.72±0.42A
BMD (mg/cm2)
Total body 50.01±1.98 47.84±1.49C 49.19±1.60 45.69±2.69A
Lumbar spine 65.16±5.15 60.01±2.98C 69.45±6.92 59.47±4.92A
Trochanter 91.51±8.95 81.16±7.47B 83.93±4.85 74.34±7.24A
Femoral shaft 71.88±7.50 66.96±4.09 65.91±3.44 59.80±3.33A
Tibia 98.18±7.05 90.51±6.66C 93.63±4.50 84.70±9.13B
Body mass, body fat, bone area and bone mineral density parameters were evaluated in vivo by repeated DXA measurements as described in the Materials and
Methods and in the legend to Fig. 1A. The table shows the data from two observation points, young (10 weeks) and adult mice (6 months). Values represent mean
± s.d.
AP<0.001; BP<0.01; CP<0.05 compared with gender-respective WT group using MANOVA; DTibial bones were measured in smaller groups of 10-week-old
mice; males: WT n=5, Sox4+/– n=6; females: WT n=7, Sox4+/– n=7.
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Bone mass in young Sox4+/– mice is reduced
We used repeated DXA (dual-energy X-ray
absorptiometry) measurements to evaluate the age-
and gender-related bone mineral content (BMC; Fig.
1A) and BMD (Table 1) in Sox4+/– and WT mice.
From 7 weeks to 12 months of age, male and female
Sox4+/– mice showed a significantly lower total bone
area and whole body BMC and BMD (P<0.001 for
all analyses of repeated measurements) compared
with their WT littermates (Fig. 1A, Table 1). When
specific regions of interest (ROI) were studied, Sox4+/– mice
had significantly lower BMD compared with WT in both the
axial (spine) and appendicular (trochanter femoris and
tibia) skeleton (Table 1). Overall, the impact of Sox4
haploinsufficiency on bone mass was manifest already by 10
weeks of age, and the differences remained throughout the
observation period (corrected for bone area and body mass in
both genders). There were no significant differences in body
fat throughout the observation period (Table 1).
Impaired bone microarchitecture in Sox4+/– mice shown
by CT
Three-dimensional CT analyses of femoral bones showed
alterations of cortical and trabecular bone microarchitecture in
Sox4+/– mice (Fig. 1B). By 3 months of age, cortical bone
volume and cortical thickness at the femoral diaphysis were
significantly lower in both male and female Sox4+/– mice
compared with WT (Fig. 1C and Table 2). Moreover, male
Sox4+/– mice showed significantly reduced total and medullary
volume of cortical bone, indicating a decreased femoral bone
size (diameter). These differences were maintained at 12 and
18 months of age (data not shown). At the distal femoral
metaphysis, trabecular thickness was decreased and trabecular
number slightly increased in 3-month-old Sox4+/– mice
compared with WT (Fig. 1C and Table 2). Trabecular bone
volume fraction (BV/TV) was decreased in males (Fig. 1C),
whereas no differences in connectivity were seen between WT
and Sox4+/– mice (Table 2). Altogether, the pattern of bone
microarchitecture in heterozygous mice suggested a reduced
bone formation during growth.
Static and dynamic bone histomorphometry in Sox4+/–
mice
Data obtained by static histomorphometry of proximal tibiae
from 3-month-old mice were similar to the CT data from
distal femur, showing lower values for trabecular BV/TV (%)
Fig. 1. Bone densitometric, morphological and
biomechanical characteristics of Sox4+/– mice compared
with WT. (A) BMC-changes with age measured with
DXA in WT and Sox4+/– mice (n=11-24). Mean age for
each measurement: 48, 70, 104, 134, 168, 182, 222, 260,
300, 335 and 374 days. The growth curves for each
genotype in both genders (corrected for body weight and
bone area) were significantly different (P<0.001)
throughout the observation period. Plots of mean BMC ±
s.d. (WT males and females: n=24; Sox4+/– males: n=11,
Sox4+/– females: n=14). Error bars on one side were
omitted for clarity. (B) Microarchitecture of diaphyseal
and metaphyseal bone from WT and Sox4+/– mice
analyzed by CT. Typical example of femurs from 3-
month-old males, left: diaphysis (cortical bone), right:
methaphysis (trabecular bone). (C) Cortical bone volume
(Cort. BV), cortical thickness, trabecular bone volume
(Trab. BV/TV, %) and trabecular thickness in 3-month-old
males. Bars, mean ± s.d. (WT: n=11, open bars; Sox4+/–:
n=8, solid bars). For cortical thickness, P=0.052.
(D) Dynamic assessment of mineral acquisition rate
(MAR) in WT and Sox4+/– mice. Fluoroscopic
microphotograph showing fluorochrome labeling in a 3-
month-old female injected with Alizarin (red) and calcein
(green) 10 and 3 days before sacrifice, respectively.
Distance between arrows: MAR during 7 days (see Table
3 for quantitative analysis). (E) Bone formation rate/bone
surface/year (BFR/BS/year) in 3-month-old males treated
as described in D. Bars, mean ± s.d. (WT: n=5, open bars;
Sox4+/–: n=4, solid bars). (F) Biomechanical properties:
moment of inertia (Ix) and stiffness in femurs from 3-
month-old males, presented as mean ± s.d. (WT: n=11,
open bars; Sox4+/–: n=8, solid bars). ***P<0.001; *P<0.05
compared with WT.
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and thickness in Sox4+/– mice versus WT (data not shown).
Osteoid volume/bone volume, osteoblast surface/bone surface
(BS) and growth plate width were all significantly lower in
tibiae from Sox4+/– mice versus WT (Table 3). The zone of
hypertrophic chondrocytes and the osteoclast surface:BS ratio
were not significantly changed, but for both there was a trend
towards reduction (Table 3). At 6 months of age,
histomorphometric analyses of tibial bones from both genders
corresponded to CT data at this age, showing no significant
differences between the WT and Sox4+/– mice for the
parameters mentioned (not shown).
Dynamic double fluorochrome labeling (using calcein and
Alizarin Red) of bone accretion showed a marked (>50%)
reduction of mineral apposition rate (MAR) in 3-month-old
Sox4+/– compared with WT mice (Fig. 1D, Table 3), consistent
with the reductions in bone formation rate (BFR; Fig. 1E) and
mineralized surface/BS (Table 3). Taken together, these results
suggested that reduced bone mass in Sox4+/– mice was because
of a defect in bone formation rather than in bone resorption.
Deteriorated bone strength in Sox4+/– mice
To evaluate the influence of Sox4 haploinsufficiency on cortical
bone mechanical properties, the area moment of inertia (Ix)
was derived from the geometrical measurements obtained by
CT, and the structural (ultimate force and stiffness) and
material (Young’s elastic modulus and ultimate stress)
properties related to fracture resistance were directly evaluated
by three-point bending of femurs. As shown in Table 4 and Fig.
1F, Ix, ultimate force and stiffness of femurs were significantly
lower in male and female Sox4+/– compared with WT mice.
However, Young’s elastic modulus and ultimate stress were
similar in male and female Sox4+/– and WT mice, indicating
that the decreased bone strength in Sox4+/– mice was due
primarily to the smaller diameter of their diaphyseal bone.
Bone formation markers and PTH/calcium status in
serum from Sox4+/– mice
The serum levels of the bone formation marker osteocalcin
(OCN) were moderately reduced in 3-month-old female
Sox4+/– mice (165.3±24.0 ng/ml; mean ± s.d.) compared with
WT (182.1±49.8 ng/ml; n=5 in both groups), but alkaline
phosphatase (ALP) activity was not (132.9±9.6 mU/ml serum
in Sox4+/– versus 114.8±6.5 mU/ml serum in WT; P<0.01; n=5
and 7, respectively). Serum levels of PTH and total calcium
measured at 6 and 12 months were similar in the WT and
Sox4+/– mice (data not shown).
Sox4+/– osteoblasts in primary cultures show serious
functional defects
The effect of Sox4 on osteoblast development and function was
Journal of Cell Science 120 (16)
Table 2. Cortical and trabecular microarchitecture of femurs from WT and Sox4+/– mice by CT analysis
Males Females
WT (n=11) Sox4+/– (n=8) WT (n=8) Sox4+/– (n=7)
Cortical bone (diaphysis)
Total volume (mm3) 1.46±0.08 1.25±0.09A 1.08±0.07 1.05±0.08
Bone volume (mm3) 0.65±0.04 0.57±0.04A 0.46±0.03 0.42±0.01B
Cortical thickness (m) 207.18±10.04 197.13±10.84D 176.75±6.45 160.86±11.98B
Medullary volume (mm3) 0.81±0.08 0.68±0.06A 0.62±0.05 0.62±0.09
Trabecular bone (distal femur metaphysis)
BV/TV (%) 18.16±1.29 15.46±3.24C 4.54±0.51 4.83±1.01
Trabecular number (/mm) 4.71±0.27 5.14±0.17A 3.68±0.34 4.19±0.27B
Trabecular thickness (m) 56.66±4.01 51.48±5.83C 38.50±3.01 33.56±1.50B
Trabecular connectivity (mm–3) 117.42±18.60 118.61±18.85 21.38±5.59 29.08±24.21
Three-dimensional microarchitectural parameters were evaluated ex vivo on excised bones from 3-month-old mice. Values represent mean ± s.d. AP<0.001;
BP<0.01; CP<0.05, DP=0.052 compared with gender-respective WT group using MANOVA.
Table 3. Histomorphometric analysis in WT and Sox4+/– mice 
Males Females
WT (n=5) Sox4+/– (n=4) WT (n=4) Sox4+/– (n=3)
Static parameters
Growth plate width (m) 105.75±7.55 84.02±2.06B 103.87±6.92 87.70±1.81B
Hypertrophic chondrocyte zone (m) 40.91±1.38 39.14±1.85 45.37±4.97 34.98±7.89
Osteoid volume/bone volume (%) 2.69±0.17 1.85±0.13A 2.20±0.21 1.59±0.19B
Osteoblast surface/bone surface (%) 15.89±0.60 10.86±2.60B 32.90±6.64 20.26±4.50B
Osteoclast surface/bone surface (%) 10.25±4.99 8.14±3.25 9.26±1.62 7.65±1.10
Dynamic parameters
Mineral apposition rate (m/day) 1.41±0.40 0.67±0.15B 1.49±0.39 0.63±0.39B
Bone formation rate/bone surface (m3/m2/year) 210.57±52.95 75.93±21.60B 258.68±72.78 94.12±16.57B
Mineralizing surface/bone surface (%) 41.06±6.18 27.76±1.95B 47.32±3.80 32.21±4.53B
Parameters from trabecular bone (proximal tibia metaphysis), analysed 100 m from distal end of growth plate excluding the endocortical surfaces (3-month-
old mice). Values represent mean ± s.d.
AP<0.01; BP<0.05 compared with WT of same gender (Student’s t-test).
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evaluated in primary calvarial cell cultures derived from
Sox4+/– and WT mice. Real-time PCR analysis showed 42%
reduction in levels of Sox4 mRNA in Sox4+/– osteoblasts versus
WT (Fig. 2A). By comparison, bone tissue from 3-month-old
male Sox4+/– mice also expressed lower levels of Sox4 mRNA
(69%; P=0.056) relative to age- and gender-matched WT mice.
Similarly, the mRNA levels for Osx, OCN, collagen type I A2
(Coll1A2) and ALP were significantly lower in the Sox4+/–
osteoblast cultures (P<0.05), whereas Runx2, BMP-2,
osteopontin (OPN), PTH/PTHrP-receptor-1 (PTHR1), PTH-
related peptide (PTHrP) and c-fos were unchanged (Fig.
2A). Osteoclast-regulating cytokines produced by primary
osteoblast cultures were largely unaffected (Table 5), as was
production of the adipocyte markers PPAR and AP-2, and the
estrogen receptor ER (data not shown). A
corresponding decline in Sox4 protein levels
was observed in Sox4+/– osteoblasts relative
to WT, as assessed by western blot analysis
(Fig. 2B), whereas ALP activity and the
number of mineralized bone nodules (by von
Table 4. Femur bone geometry and strength in WT and Sox4+/– mice
Males Females
WT (n=11) Sox4+/– (n=8) WT (n=7) Sox4+/– (n=8)
Moment of inertia, Ix (mm4) 0.279±0.026 0.208±0.029C 0.149±0.021 0.136±0.014
Ultimate force (N) 20.4±1.4 16.7±1.6C 12.8±1.7 10.8±1.1A
Stiffness (N/mm) 135.2±15.2 117.3±14.1A 93.3±16.0 79.8±10.6
Young’s elastic modulus, E (MPa) 3506±647 4089±732 4469±435 4221±676
Ultimate stress (GPa) 108.6±10.2 110.3±8.4 109.9±9.3 100.0±10.8
Values are mean ± s.d. as derived from CT (Ix) and evaluated by three-point bending of femurs from 3-month-old mice. AP<0.001; BP<0.01; CP<0.05
compared with gender-respective WT group using MANOVA.
Fig. 2. Primary cultures of calvarial osteoblasts
derived from Sox4+/– and WT mice. (A) Real-
time PCR analyses of osteoblast characteristic
mRNAs extracted from Sox4+/– and WT primary
osteoblast cultures: Osx, osterix; OCN,
osteocalcin; Coll1A2, collagen1A2; ALP,
alkaline phosphatase; Runx2; BMP-2, bone
morphogenetic protein-2; OPN, osteopontin;
PTHR1, PTH/PTHrP-receptor-1; PTHrP, PTH-
related peptide. Results (from three independent
experiments) were normalized to -actin or
GAPDH, and expression in Sox4+/– cells is
presented relative to WT (set to 1, broken line).
(B) Representative immunoblot of lysates from
WT and Sox4+/– osteoblasts, using anti-Sox4 and
anti-actin antibodies as described in the Materials
and Methods. (C) Representative micrographs of
ALP histochemical staining (20 magnification)
in WT and Sox4+/– osteoblasts cultured for 7 days
(n=4). (D) Biochemical quantification of ALP
activity in the osteoblast cultures shown in C.
(E) Micrographs of von Kossa-stained osteoblast
cultures (20 magnification) demonstrating
mineralization (dark areas) of nodules after 3
weeks of culture in medium containing ascorbic
acid and -glycerophosphate. (F) Densitometric
quantification of von Kossa-stained mineralized
nodules expressed as per cent of WT staining. In
each of three independent experiments, 4-10
representative microscopic fields were examined.
(G) Incorporation of [3H]thymidine in
proliferating osteoblasts. Data from two
independent experiments were normalized and
compared with mean WT values (n=24 for each
genotype). Bars, mean ± s.d. ***P<0.001,
*P<0.05, unpaired Student’s t-test (with Welch
correction in F).
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Kossa staining) were reduced by approximately 40 and 60%,
respectively (Fig. 2C-F). The total cell number in Sox4+/–
calvarial cultures was markedly lower compared with WT
(52±13 and 88±23, P<0.01; n=3). However, the relative
fraction of ALP-positive cells was even further reduced
(50±13% and 81±8% in Sox4+/– and WT osteoblasts,
respectively; P<0.001). Moreover, we assessed the
proliferative capacity of Sox4+/– osteoblasts by thymidine
incorporation, and found that it was severely impaired, being
only 27% relative to WT (Fig. 2G). Taken together, these data
demonstrate Sox4+/– osteoblast insufficiency in vitro.
No functional defects detected in bone marrow-derived
primary cultures of Sox4+/– osteoclasts
No differences in typical osteoclastogenic properties were
detected, as judged by the number of tartrate-resistant acid
phosphatase (TRAcP)-positive multinucleated cells (96±33%
in Sox4+/– cells versus WT; n=4) and the ability to erode bone
in vitro, shown as functional pit index assay (119±35.2% in
Sox4+/– cells versus WT; n=4). WT osteoclastic cells cultured
in the presence of conditioned cell media from Sox4+/–
osteoblasts showed unchanged light microscopic morphology,
phenotype and functional activity (not shown).
Sox4 siRNA modulates WT osteoblast function,
mimicking Sox4 haploinsufficiency
To study the effect of knockdown of Sox4, we treated primary
calvarial osteoblasts from WT mice with siRNA against Sox4
or with scrambled siRNA as control. Real-time PCR
demonstrated a decline in levels of Sox4 mRNA by 63%
relative to control cells (Fig. 3A). Significant reductions in
mRNA levels were found also for Osx, OCN, Coll1A2,
PTHR1, PTHrP (29-52%) and ALP (75%), whereas Runx2
and OPN were not affected (Fig. 3A). Cell
proliferation analysis replicated previous results
in Sox4+/– osteoblasts: Sox4 siRNA reduced
[3H]thymidine incorporation by 54% compared with
WT (Fig. 3B). Furthermore, the number of cells
staining positive for ALP was reduced by 31% and
ALP enzymatic activity by 33% (Fig. 3C-E). Similar
to the Sox4+/– osteoblast cultures described above,
Sox4 siRNA treatment caused lower cell numbers
(41±1.5 versus 61±6.3), and relative reductions in
the number of ALP-positive cells (44±7% in Sox4
siRNA-treated cultures versus 64±14% in the
control cultures, P<0.05). We did not find evidence
Journal of Cell Science 120 (16)
Table 5. Osteoclast-regulating cytokines produced by
primary osteoblast cultures from WT and Sox4+/– mice
Sox4+/–/WT ratio
(n=3)
IL-1 1.29±0.29 
IL-6 0.77±0.2 
M-CSF 0.99±0.08 
PTHrP 1.16±0.16
TNF 1.11±0.34 
RANKL 0.76±0.24 
OPG 0.90±0.25 
IL-12 1.18±0.43 
IL-18 0.93±0.23 
GM-CSF 1.40±0.49 
mRNAs of osteoclast-regulating cytokines characteristically produced by
primary osteoblasts in culture, quantified by real-time RT-PCR and reported
as mean expression (± s.d.) in Sox4+/– osteoblast cultures relative to WT (set
equal to 1; n=3, each time performed in triplicate). Student’s t-tests revealed
no significant differences between WT and Sox4+/– cultures.
Fig. 3. Silencing of Sox4 mRNA in WT primary
osteoblast cultures with siRNA. (A) Real-time RT-PCR
analyses of mRNA levels in siRNA-treated osteoblasts
expressed relative to osteoblasts treated with control
(scrambled) siRNA (set to 1, broken line), and normalized
to GAPDH mRNA. Osx, osterix; OCN, osteocalcin;
Coll1A2, collagen1A2; ALP, alkaline phosphatase;
Runx2; OPN, osteopontin; PTHR1, PTH/PTHrP-receptor-
1; PTHrP, PTH-related peptide. (B) Incorporation of
[3H]thymidine in proliferating WT osteoblasts following
treatment with control or Sox4 siRNA, respectively.
(C) Photomicrographs of WT osteoblast cultures treated
with control or Sox4 siRNA, respectively, stained for
ALP activity. (D) Quantification of ALP-positive cells per
well in C. (E) Biochemical activity of ALP in siRNA-
treated osteoblasts. (F) mRNA levels of Runx2, OCN and
Sox4 following treatment of WT cells with specific Runx2
siRNA compared with control siRNA, quantified by real-
time RT-PCR and related to GAPDH mRNA as control
(set to 1, broken line). In A,B,D-F: ***P<0.001, *P<0.05
versus siRNA control (ctrl); bars, mean ± s.d. of
triplicates (n=2).
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that treatment of osteoblasts with Sox4 siRNA induced
apoptosis (data not shown).
Runx2 siRNA modulates osteoblast differentiation
without affecting Sox4 expression
Our data showing reduced expression of two typical Runx2-
dependent genes, Osx and OCN, both in Sox4+/– and Sox4
siRNA-treated osteoblasts, might suggest that Sox4 and Runx2
are part of the same molecular pathway involved in regulating
osteoblast development and/or function. Thus, gene silencing
of Runx2 by siRNA technology was used to assess whether
Sox4 is affected by decreased Runx2 levels in mouse primary
calvarial osteoblasts. We found no effect of Runx2 knockdown
on Sox4 mRNA expression, whereas Runx2 and OCN mRNA
levels were downregulated by 65% and 62%, respectively
(Fig. 3F). These results suggest that Sox4 action on
osteoblastogenesis is independent of the Runx2 pathway (Fig.
4).
Discussion
Sox4 belongs to a family of HMG box transcription factors
regulating numerous developmental processes. In this study we
have characterized the skeletal phenotype of Sox4+/– mice and
the functional role of Sox4 in osteoblasts. Our results establish
that Sox4 is important for normal postnatal bone development,
through effects on osteoblast development or function.
Even though Sox4+/– mice thrived and exhibited normal
gross anatomy from birth, bone mass indices were significantly
reduced (compared with WT littermates) already by 7-10
weeks of age. Histomorphological analyses showed reduced
thickness of cortical and trabecular bone, in addition to
markedly lower (>50%) BFR and MAR, in 3-month-old
Sox4+/– mice versus WT. Importantly, biomechanical bone
strength (fracture resistance) in femur was also affected, most
likely because of a smaller diaphyseal diameter. In light of the
striking reductions in MAR and other histomorphometric
parameters (Table 3), we cannot exclude the possibility that
the relatively modest quantitative effects of Sox4
haploinsufficiency on bone mass parameters in vivo may
involve compensatory mechanisms. However, dynamic
parameters for bone formation velocity at a given time (MAR,
BFR) are not directly comparable to BMC, which integrates
net mineralized bone tissue formed over the lifetime of the
animal. Nevertheless, our results clearly demonstrate that
Sox4+/– mice exhibit an osteopenic phenotype, including
impaired bone structure and biomechanical strength, mainly
caused by suppressed bone formation and/or mineralization in
early life.
The differences between Sox4+/– and WT mice appear most
pronounced at 3 months of age; in addition to bone mass, the
differences in femoral length and bone structure (by CT and
static histomorphometry) peaked at 3 months and lost
significance in older age. Moreover, our histomorphometry
data showing reduced osteoid volume in bones from Sox4+/–
mice do not support a mineralization defect (e.g. osteomalacia)
as a major responsible factor for the observed low bone mass.
These findings strongly indicate that Sox4 is a limiting factor
for normal bone development during periods of active and
intense growth. Following peak bone mass and skeletal
maturation, the osteopenia did not worsen but was maintained
in both genders during adult life, suggesting that in later stages
of adulthood, reduced levels of Sox4 are sufficient to sustain
normal bone homeostasis. Importantly, our results also indicate
that the bone phenotype in Sox4+/– mice cannot be fully rescued
by other members of the Sox family.
The suboptimal skeletal development and osteopenic
phenotype in Sox4+/– mice are interesting in relation to genetic
factors regulating early stages of bone formation. We have
previously shown that Sox4 mRNA is highly expressed in
hypertrophic chondrocytes of the mouse embryonic growth
plate during early phases (ED15.5) of endochondral bone
development, and also by human and rodent osteoblasts in vitro
(Reppe et al., 2000). Whereas cRNA in situ hybridization was
not sufficiently sensitive to detect Sox4 mRNA in osteoblasts
in vivo, real-time PCR enabled us to verify reduced Sox4
expression in bones from Sox4+/– mice relative to WT (in vivo),
as well as in the respective calvarial osteoblast cultures derived
from these animals (in vitro).
Another group has reported that highest levels of SOX4
mRNA expression were seen in the proliferative phase during
the course of human osteoblast development (Billiard et al.,
2003). In the present study we found severely impaired
proliferation of Sox4+/– osteoblasts, as assessed by a decreased
thymidine incorporation rate of 73%, and reduced numbers of
cells. In support of these observations, preliminary cell-cycle
analyses indicated delayed S-phase progression and slower
passage into the G2 phase in Sox4+/– osteoblasts (data not
shown), suggesting that it takes mutant cells longer to traverse
the cell cycle. Delayed osteoblast maturation was also
demonstrated in Sox4+/– calvarial cultures, with Osx, OCN,
Coll1A2 and ALP mRNA levels selectively reduced (25-70%),
whereas the other mRNAs investigated were not changed.
These changes in the osteoblast gene expression pattern in
Sox4+/– cells were almost entirely mimicked by siRNA
treatment of WT osteoblasts (with the exception of PTHR1 and
PTHrP, see below). By contrast, no significant effect of the
 tsalboetsO llec rotinegorpoetsO PreosteoblastProliferation Differentiation 
Sox4 Osterix 
Runx2 
Fig. 4. Proposed model of Sox4 regulation
of osteoblast proliferation and
differentiation. Represented is the hierarchy
of the osteoblast lineage and the predicted
Sox4 actions. According to the experimental
data, Sox4 could affect proliferation of
osteoprogenitors as well as differentiation of
mature osteoblasts. This latter action could
be exerted by downregulation of osterix,
with a mechanism apparently independent of
Runx2.
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Sox4 mutation was observed on osteoclast development and
function in vitro. Hence, our data support a predominant effect
of Sox4 deficiency on bone formation, and implicate this
transcription factor as an important regulator of osteoblast
proliferation. Whether the delay in osteoblast maturation, at
least partly, is secondary to the defect in proliferation remains
to be established.
The localization of SOX4 to chromosome 6p22 (in humans)
and 13 (in mice) (Critcher et al., 1998) coincides with a
mapped chromosomal region recently predicted to comprise a
gene with pleiotropic effects on osteoblast activity, number or
recruitment in baboons (Havill et al., 2006) and to affect BMD
in mice (Shimizu et al., 2002). In light of our data in the present
study, it will be important (in future research) to clarify
whether this gene is identical to Sox4. The upregulation
of human SOX4 mRNA in patients with primary
hyperparathyroidism (Reppe et al., 2006), together with our
results that SOX4 is downregulated in postmenopausal primary
osteoporosis (K.M.G., S.R., V.T.G., R.J., F.P.R., L.S.H.N.-M.
and O. K. Olstad, unpublished), strengthen the concept that
SOX4 has a functional role in human bone metabolism.
Acute Sox4 knockdown (>50% by siRNA) in normal
calvarial osteoblasts in vitro reduced the mRNA levels for
PTHR1 and PTHrP, which is interesting also in light of our
previous observation that Sox4 is a PTH-responsive gene
(Reppe et al., 2000). Thus, Sox4 is not only a target for PTHR1
signaling, but may also be part of a regulatory loop that
modulates the PTH/PTHrP-receptor system (Kronenberg,
2006). This effect of Sox4 gene silencing on PTHR1 and
PTHrP mRNAs was clearly distinct from the pattern found in
Sox4+/– osteoblasts, and the reason for the apparent discrepancy
between long-term versus acute effects of Sox4 deficiency
remains to be clarified.
The transcription factors Runx2 and Osx play crucial roles
in osteoblastogenesis, as indicated by severe defects in bone
development following knockout of these genes (Komori et al.,
1997; Nakashima et al., 2002). Runx2, an important regulator
of the osteoblast-related protein OCN (Ducy, 2000; Gaur et al.,
2005), also modulates ALP and Osx expression, whereas Osx
is not required for expression of Runx2 (Nakashima et al.,
2002). Thus, Osx acts downstream of Runx2 to regulate
osteoblast differentiation (Nakashima et al., 2002), but also
mediates other signaling pathways including BMP-2 and IGF-
1 (Celil et al., 2005), independent of Runx2. Our results from
Sox4 siRNA experiments are in agreement with a Runx2-
independent mechanism for Sox4 action in osteoblast
development. Whereas mRNA for Osx was markedly
decreased in Sox4 siRNA-treated WT osteoblasts, as well as
in Sox4+/– osteoblast cultures, Runx2 was not affected.
Furthermore, treatment of WT osteoblasts with Runx2 siRNA
did not reduce Sox4 expression. It is possible that the effect of
Sox4 on osteoblast development, as assessed by mRNAs for
ALP and OCN, is mediated by Osx, but independent of Runx2
(Fig. 4). Analysis of the promoter sequences of OCN (data not
shown) and Osx (Lu et al., 2006) revealed several putative
binding sites for Sox-like transcription factors in these genes;
therefore, direct transcriptional regulation through Sox4 cannot
be excluded.
Growth plate width was significantly reduced in limbs from
Sox4+/– mice, suggesting that chondrocytes are also affected by
Sox4 deficiency (Table 3). Because there was no evidence for
alterations in the number or activity of osteoclasts/
chondroclasts in bones from Sox4+/– mice, the primary
responsible mechanism for reduced growth plate width is most
likely related to reduced ability of columnar chondrocytes to
proliferate and subsequently undergo hypertrophy (Vanky et
al., 1998). The zone of hypertrophic chondrocytes was slightly
diminished, although not significantly, in the same limbs
(Table 3). It is also noteworthy that (activated) PTH/PTHrP
receptors delay chondrocyte hypertrophy through both Runx2-
dependent and -independent pathways (Guo et al., 2006).
Whether reduction in growth plate width in Sox4+/– mice
relative to WT is associated with disturbances in PTHR1-
mediated signaling in chondrocytes, and the potential
involvement of Runx2 (through dependent and independent
pathways) in this process, are interesting topics that need to be
addressed in further studies.
In conclusion, we have characterized the skeletal phenotype
of Sox4 haploinsufficient mice and investigated the functional
role of Sox4 deficiency in osteoblastogenesis in vitro. Our
results demonstrate that Sox4 influences bone formation both
in vivo and in vitro, by modulating osteoblast maturation and
function. These results implicate Sox4 as an important
regulator of osteoblast proliferation and differentiation, and
suggest that Sox4 action is mediated at least partly by Osx, but
is independent of Runx2. Finally, we find that Sox4 deficiency
results in reduced growth plate width, with the capacity to
modulate skeletal growth.
Materials and Methods
Animal breeding
Sox4+/– heterozygous mice from a C57Bl/6 background were a gift from Hans
Clevers (Hubrecht Laboratory, Netherlands Institute for Developmental Biology,
Utrecht, The Netherlands) (Schilham et al., 1996), and all mice used in the present
study have been backcrossed in the same strain for >10 consecutive generations.
The animals were kept and bred in local animal facilities in Oslo, Norway and
L’Aquila, Italy, following FELASA guidelines, and all animal procedures were
approved by the committees for animal research in Norway and Italy. Pups were
separated and earmarked at 3 weeks of age, and the resulting earpieces were used
for genotyping using a DNeasy tissue purification kit (Qiagen) and PCR with two
sets of specific primers: NEO749 (forward) 5-ACAAGATGGATTGCACGCAGG-
3, NEO1119 (reverse) 5-GAATGGGCA GGTAGCCGGATC-3; Neo-f1 (forward)
5-AGGATCTCCTGTCATCTCACCT TGCTCCTG-3 and Neo-rev1 (reverse)
5-AAGAACTCGTCAAGAAGGCGAT AGAAGGCG-3 (Invitrogen). Before
preparation of osteoblast and osteoclast cultures (postnatal day 8-10), genotyping
was performed on earpieces obtained at day 6-8.
BMD and BMC measurements
Sox4+/– mice and WT littermates were at regular time intervals anaesthetized with
subcutaneous (s.c.) injections of Hypnorm (Cilag) and Dormicum (Roche; 0.05-
0.075 ml/kg, working solution: 1.25 mg/ml midazolam, 2.5 mg/kg fluanisone and
0.079 mg/kg fentanyl citrate), and subjected to BMD/BMC measurements by DXA
in a PIXImus densitometer (GE Medical systems/Lunar Corp.). Calibrations were
performed with a phantom mouse with a defined value, and quality assessments
were performed before each use. The coefficient of variation for total BMD is
0.59%.
ROIs were analyzed using the PIXImus software (v1.46) and include total body
(the calvarium, mandible and teeth were excluded), three lumbar vertebrae (ca
1755-59 pixels), trochanter femoris, femoral midshaft and proximal tibia of right
hindlimb (all 1711 pixels). Age- and sex-matched groups of mice were measured
repeatedly at ~6-week intervals for 12 months, starting at 7-10 weeks.
Measurements were performed twice with animal repositioning between scans, and
mean values were analyzed using Microsoft Excel. Repeated measurements (ex
vivo) of identical bone areas with repositioning gave a coefficient of variation of
±1.4%.
Dynamic and static histomorphometry
10-week-old Sox4+/– and WT mice were injected subcutaneously with Alizarin
Complexone (Sigma; 20 mg/kg body weight) and calcein (Fluka; 30 mg/kg body
weight) 10 and 3 days before sacrifice, respectively (Marzia et al., 2000). Both tibiae
were dissected and fixed in 4% formaldehyde followed by embedding in a methyl
Journal of Cell Science 120 (16)
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methacrylate resin (Technovit 9100 New; Heraeus Kulzer GmbH, Wehrheim,
Germany) for dynamic histomorphometry. The following parameters were
calculated: MAR (m/day), BFR/BS (m3/m2/year) and mineralizing surface
(MS/BS, %).
Histomorphometric measurements were performed as previously described
(De Benedetti et al., 2006; Marzia et al., 2000) and with the suggested
nomenclature (Parfitt et al., 1987). Briefly, one tibia from each animal was
sectioned longitudinally through the frontal plane. Undecalcified sections (~2 m-
thick) were stained with Methylene blue/azure II for quantitative analysis of
structural variables of trabecular metaphyseal bone, and osteoblasts. Osteoclasts
were evaluated in adjacent sections treated for the cytochemical demonstration of
TRAcP. The following variables were measured in the proximal tibia: (1)
trabecular bone volume/tissue volume (BV/TV, %); (2) trabecular thickness (m),
trabecular number (no./mm) and trabecular separation (m), derived according
to the parallel plate model (Parfitt et al., 1983) and measured in the same
zone as BV/TV; (3) growth plate width (m) and size of the hypertrophic
chondrocyte zone (m); (4) osteoid volume (OV/BV, %) and osteoblast
surface (%); (5) osteoclast surface (%). Osteoid volume, osteoblasts and
osteoclasts were measured in a metaphyseal region extending at least 100 m
away from the distal end of the growth plate and excluding the endocortical
surfaces.
CT scanning
We assessed trabecular and cortical bone architecture using CT (CT40; Scanco
Medical AG, Basserdorf, Switzerland), employing a 12-m isotropic voxel size.
Specifically, trabecular bone architecture was evaluated at the distal femoral
metaphysis, whereas cortical bone morphology was evaluated at the femoral mid-
shaft, as previously described (Bouxsein et al., 2005; Ferrari et al., 2005). Bones
from mice aged 3, 6, 12 and 18 months were examined.
For all CT evaluations, we used a nominal isotropic voxel size of 12 m.
Morphometric parameters, including BV/TV (%), trabecular number (mm–1),
trabecular thickness (m), trabecular separation (m), structure model index (SMI)
and connectivity density (mm–3), were computed without assumptions regarding the
underlying bone architecture (Hildebrand and Ruegsegger, 1997). At the femoral
midshaft, 50 transverse CT slices were obtained and used to compute the total
volume within the periosteal envelope (mm3), cortical bone volume (BV, mm3),
medullary volume (mm3) and cortical thickness (m). We also used the CT images
to measure the bone inner and outer diameter (ri and ro, mm). The femurs were
approximated as perfect tubes and the area moments of inertia (Ix, mm4) at the
midshaft approximated by Ix=(ro4–ri4)/4.
Femur biomechanical testing
Bones from 3-month-old mice were rehydrated at room temperature in phosphate-
buffered saline (PBS) and femoral biomechanical properties were assessed by three-
point bending (Brodt et al., 1999; Jepsen et al., 2003), using the Instron Microtester
5848 (Instron, Norwood, MA) equipped with a 100-N gauge and custom bone
supports with a 7-mm distance. Load was applied at a constant rate (0.02 mm/sec)
until failure and the force-displacement data sampling was set to 100 Hz. We
measured the ultimate force (N) and bending stiffness (N/mm) from the load-
displacement curve and computed the Young’s elastic modulus, E (GPa), and
ultimate stress (MPa) using the relevant mid-femoral cross-sectional geometry
measured from CT and following the method described by Schriefer et al.
(Schriefer et al., 2005).
Serum analyses
Serum was collected from WT and Sox4+/– mice sacrificed at the same time of the
day to avoid diurnal fluctuations of serum markers. Measurements of total serum
calcium and PTH were performed using the QuantiChrom Calcium Assay Kit
(DICA-500; BioAssay Systems, Hayward, CA) and the Mouse Intact PTH ELISA
Kit (Immunotopics, San Clemente, CA), following the respective protocols. Serum
OCN was measured using the Mouse Bone Panel 1B Lincoplex kit (Cat# MBN1B-
41K) following the manufacturer’s protocol (LINCO Research, St Charles, MO),
and analyzed with a BioPlex luminometer (Bio-Rad Laboratories). ALP activity was
measured as described (Dimai et al., 1998).
Primary cultures of mouse calvarial osteoblasts
Osteoblast cultures were derived from 8-day- to 10-day-old Sox4+/– and WT mice
of both genders as described (Marzia et al., 2000). Initial experiments using separate
osteoblasts from male and female mice showed similar results for all functional
parameters tested. We therefore used gender-mixed osteoblast cultures for most
experiments. Briefly, dissected calvariae were sequentially digested with 1 mg/ml
Clostridium histiolyticum type IV collagenase (Sigma) and 0.025% trypsin (Becton
Dickinson) in Hank’s buffered solution. Cells from second and third digestions were
grown in Dulbecco’s modified Eagle’s medium (DMEM) with antibiotics and 10%
fetal bovine serum (FBS). At confluence, cells were trypsinized, counted and plated
in appropriate vessels for further experiments. All experiments were performed on
7-day cultures or as indicated. Cell culture media and supplements were purchased
from Invitrogen (Carlsbad, CA).
Western blotting
Cells were lysed in RIPA buffer (50 mM Tris HCl, pH 7.5, 150 mM NaCl, 1%
Nonidet P-40, 0.5% sodium deoxycholate, 0.1% SDS) containing protease
inhibitors. 100 g proteins were resolved under reducing conditions by 12% SDS-
PAGE and transferred to nitrocellulose membranes. Following blocking of the blot
with 5% non-fat milk in TBS-T buffer (20 mM Tris-HCl, pH 7.6, 137 mM NaCl,
0.2% Tween 20), the anti-Sox4 primary antibody (Chemicon International, cat.
#AB5803) was diluted 1:200 (in 1% non-fat milk in TBS-T) and incubated with the
blot for 1 hour at room temperature. Next, the filter was washed 310 minutes in
TBS-T and incubated with the appropriate horseradish peroxidase (HRP)-
conjugated secondary antibody for 1 hour at room temperature. Protein bands were
revealed by ECL detection. The filter was then stripped and reprobed with anti-actin
antibody (Santa Cruz Biotechnology, Heidelberg, Germany, cat. #SC-1616) for
normalization.
Proliferation
The procedure was modified from Marzia et al. (Marzia et al., 2000). Briefly,
osteoblasts were plated in 24-well multiplates (5000 cells per well) and grown to
~70% confluence. Following incubation for 24 hours in DMEM with antibiotics and
0.2% bovine serum albumin (BSA), the cells were incubated in 1 Ci/ml
[3H]thymidine (specific activity 5.0 Ci/mmol; Amersham) overnight. Cells were
then washed twice and solubilized in 0.1% SDS. 10 l 10 mg/ml BSA was added
to each sample as a carrier protein, and precipitated by adding 100 l 100%
trichloroacetic acid (TCA) and incubating for 30 minutes on ice. Following
centrifugation, the precipitate was resuspended in 0.5 ml 0.1% SDS. 5 ml Insta-Gel
II scintillation fluid (Packard Instrument Company, Groningen, The Netherlands)
was added and the samples were counted in a -scintillation counter (Packard Tri-
Carb 1900TR).
ALP activity of osteoblasts
Differentiation was evaluated by histochemical and biochemical analyses of ALP
activity using reagents and protocols from Sigma kit 104-LS. Total numbers and
numbers of ALP-positive cells were mean counts of three microscopic fields from
three cultures of WT and Sox4+/– mice (magnification 20). For siRNA experiments
(see below), cells were counted from two cultures (two experiments) of WT
osteoblasts treated with Sox4 and control siRNA.
Mineralization
Osteoblasts were plated in 6- or 24-well multiplates and grown to 90% confluence
(~7 days following plating). Media were then replaced with mineralizing media
(DMEM supplemented with 10% FBS, 50 g/ml ascorbic acid and 10 mM -
glycerophosphate) and cultured for 3 weeks with medium change every 3 days, as
described (Marzia et al., 2000). Mineralization was evaluated by von Kossa staining,
counting and quantification of positive nodules in 10 representative microscopic
fields.
RNA isolation and real-time PCR
Total RNA was isolated from mouse bones and cell cultures using Trizol® (Life
Technologies/Invitrogen, MD) and further purified by RNeasy Mini Kit (Qiagen,
Hilden, Germany). RNA quality was checked using a Matrix 2100 Bioanalyzer
(Matrix AS, Oslo, Norway) and results analyzed by Agilent 2100 expert software
(Agilent Technologies, Blacksburg, VA).
1 g of RNA was subjected to a 20 l reverse transcriptase (RT) reaction by M-
MLV Reverse transcriptase (Promega, Madison, WI) according to the
manufacturer’s procedure, and diluted 5 before samples (in triplicates) were
subjected to real-time PCR analysis in a LightCycler (Roche Diagnostics, Penzberg,
Germany). LightCyclerTM Fast Start Master SYBR Green (Roche Diagnostics) or
Brilliant® SYBR Green QPCR master mix (Stratagene) kits were used. PCR
conditions and primer pairs used are listed in Table S1. To distinguish cDNA and
genomic DNA, primers were placed on corresponding exons at the junction of an
intron. In addition to this, we also used primers for ALP, Coll1A2 and PTHR1 as
published (Huang et al., 2004), OCN (zur Nieden et al., 2003), c-fos (Tanaka et al.,
2004) and AP2 (Jiang et al., 2004).
Cycle threshold (Ct) values were obtained graphically (Roche Diagnostics,
software version 3.5). Gene expression was normalized to -actin or GAPDH and
	Ct values calculated. Comparison of gene expression between two samples (WT
and Sox4+/– bones or osteoblasts) was obtained by subtraction of 	Ct values between
the two samples to give a 		Ct value, and relative gene expression calculated as
2–		Ct normalized to WT.
Osteoclast primary cultures
Differentiated primary osteoclasts were obtained from the bone marrow of 5-7-day-
old Sox4+/– and WT mice by a modification of the method described by David et
al. (David et al., 1998; Teti et al., 1999). Pups were sacrificed by cervical dislocation,
and long bones were dissected free from soft tissues and cut into small fragments.
Bone marrow cells were released by gently pipetting the fragments in DMEM
supplemented with 100 IU/ml penicillin, 100 g/ml streptomycin, 2 mM L-
glutamine and 10% FBS. Cells were plated in culture dishes and allowed to attach
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for 24 hours before non-adherent cells were removed by aspiration and extensive
washing. The total adherent cell fraction was cultured for up to 7 days in the
presence of 10–8 M 1,25(OH)2vitamin D3.
Cultures were fixed in 3% paraformaldehyde in 0.1 M cacodylate buffer, and
positivity for the osteoclast marker enzyme TRAcP was detected histochemically
using the Sigma-Aldrich kit No. 85 (Sigma), according to the manufacturer’s
instructions.
Osteoclasts were also grown on bone slices, differentiated as described above,
and fixed in 3% paraformaldehyde in 0.1 M cacodylate buffer. Cells were then
removed by ultrasonication in 1% sodium hypochlorite, and slices were stained with
0.1% toluidine blue. Pits were counted and the pit index computed according to
Caselli et al. (Caselli et al., 1997).
RNAi knockdown of gene expression in WT osteoblasts
Four siGENOMETM SMART pool® siRNA duplexes specific for mouse Sox4 were
designed by and purchased from Dharmacon (Lafayette, CO). Osteoblasts from
calvariae of 7-day-old WT mice were trypsinized and plated in 24-well plates or in
3.5 cm culture dishes. At approximately 50% confluence, cells were transfected
with the annealed siRNA-Sox4 (siRNA final concentration 100 nM) using
oligofectamine (Invitrogen, Carlsbad, CA) in Opti-MEM (Invitrogen). Cells were
treated with siRNA-Sox4 for 48 hours, then the RNA was extracted, reverse
transcribed and subjected to amplification for the Sox4 gene in order to evaluate its
downregulation. The same procedure was followed for RNAi knockdown of Runx2.
Statistical analyses
Results are generally expressed as means ± s.d. and analyzed by SPSS v12.0.1.
Analyses of bone density time courses were performed using SPSS Mixed Models,
taking into account the repeated measurements of each mouse parameter and the
dependency of DXA parameters within each individual. Time, genotype and gender
were analyzed statistically as fixed effects, with bone area, per cent fat and body
mass as covariates for analyses with total BMC and BMD as dependent variables,
respectively. Variables obtained from the same bone (DXA-/CT-results,
histomorphometry, biomechanics) were considered as dependent data sets and
analyzed by multivariate analyses (MANOVA). Independent data sets were analyzed
with unpaired Student’s t-test, using Welch correction when variances were unequal.
For all statistical tests, P<0.05 was considered significant.
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